SCHEMBL23461460

SCHEMBL23461460

CC1([C@H](NC(=O)c2ccc3cc(F)ccc3c2OCc2ccc(OC(F)(F)F)cc2)C(=O)O)CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.35
▸ OPRM1 P35372 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ GCGR P47871 1/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ GPR132 Q9UNW8 1/20 0.33
▸ SLC2A1 P11166 1/20 0.33
▸ SLC2A3 P11169 1/20 0.33
▸ SLC2A4 P14672 1/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ ABHD6 Q9BV23 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ MRGPRX4 Q96LA9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38146994 1.00 CXCR2 (0.37) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23461461 1.00 CXCR2 (0.37) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23461079 0.97 CXCR2 (0.38) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL38666141 0.97 CXCR2 (0.38) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23461080 0.97 CXCR2 (0.38) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL38663896 0.91 OPRM1 (0.37) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23460869 0.91 OPRM1 (0.37) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23460872 0.91 OPRM1 (0.37) CXCR2CYP3A4CYP2C9CYP2C19FFAR4
SCHEMBL23460874 0.90 CXCR2 (0.46) CXCR2CYP3A4PPARACNR2CNR1
SCHEMBL23460875 0.90 CXCR2 (0.46) CXCR2CYP3A4PPARACNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885CYP3A4 601/4885CYP2C9 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback